Anzeige
Mehr »
Login
Mittwoch, 02.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: BAY001 | ISIN: DE000BAY0017 | Ticker-Symbol: BAYN
Xetra
01.04.25
17:40 Uhr
22,315 Euro
+0,245
+1,11 %
1-Jahres-Chart
BAYER AG Chart 1 Jahr
5-Tage-Chart
BAYER AG 5-Tage-Chart
RealtimeGeldBriefZeit
22,25022,38501.04.
22,25022,39001.04.
ACCESS Newswire
765 Leser
Artikel bewerten:
(2)

injuryclaims.com: Jury Hits Bayer with $78 Million Verdict in Roundup Cancer Case

Finanznachrichten News

Philadelphia Court Rules in Favor of Plaintiff Claiming Roundup Caused Non-Hodgkin's Lymphoma

PHILADELPHIA, PA / ACCESSWIRE / October 10, 2024 / A Pennsylvania jury has ruled against Bayer, awarding $78 million to William Melissen, who alleged that his cancer was caused by exposure to the Roundup weedkiller. The jury's decision includes $3 million in compensatory damages and $75 million in punitive damages, adding to the ongoing legal challenges Bayer faces over its glyphosate-based product.

Melissen's case is one of many that claims Roundup's active ingredient, glyphosate, led to the development of non-Hodgkin's lymphoma. Despite Bayer's continued assertion that glyphosate is safe and supported by scientific research, the verdict signals a significant outcome in the broader dispute over the herbicide's safety.

Bayer Roundup Verdict Adds to Ongoing Litigation Over Cancer Risks

Bayer has experienced mixed results in courtrooms nationwide regarding Roundup claims. This verdict follows a pattern of high-stakes decisions, even as the company has managed to secure victories in several previous cases. With thousands of cases still pending, this latest ruling indicates that the legal landscape around glyphosate exposure remains active.

Bayer remains steadfast in its position, emphasizing that its product is backed by scientific evidence and regulatory reviews. Following the jury's decision in the Melissen case, Bayer announced its intention to appeal, aiming to reduce the punitive damages awarded.

Legal Options for Roundup Cancer Victims

Individuals who believe they developed cancer after using Roundup may have legal options to seek compensation. Consulting with a knowledgeable attorney can provide clarity on the next steps for filing a claim. For more details, visit Injury Claims or learn more about the Class Action Lawsuits available to those affected.

If you or a loved one were exposed to glyphosate and subsequently diagnosed with cancer, now is the time to reach out for legal guidance.
For more information about Roundup cancer litigation, visit https://injuryclaims.com/roundup-lawsuit.

CONTACT:
Gino Aielli
Typhon Interactive
Phone: (307) 213-4486
Email: info@typhoninteractive.com

SOURCE: injuryclaims.com



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.